
|Videos|November 19, 2017
Dr. Capitanio Discusses Adjuvant Therapy for High-Risk Kidney Cancer
Author(s)Umberto Capitanio, MD
Umberto Capitanio, MD, FEBU, department of Urology, San Raffaele Scientific Institute, University Vita-Salute San Raffaele, discusses adjuvant therapy for patients with high-risk kidney cancer without metastases.
Advertisement
Umberto Capitanio, MD, FEBU, Department of Urology, San Raffaele Scientific Institute, University Vita-Salute San Raffaele, discusses adjuvant therapy for patients with high-risk kidney cancer without metastases.
In the United States, sunitinib (Sutent) is now approved for the adjuvant treatment of this population. In Europe however, guidelines do not recommend the use of adjuvant therapy due to conflicting published results.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on OncLive
1
FDA Accepts BLA for Ivonescimab Plus Chemotherapy in EGFR-Mutant NSCLC After TKI Progression
2
The OncFive: Top Oncology Articles for the Week of 1/25
3
HPV Vaccination and Evolving Screening Strategies Continue to Shape Cervical Cancer Prevention Efforts
4
FDA Approval Sought for Lirafugratinib in Second-Line, FGFR2-Altered Cholangiocarcinoma
5


































